Skip to content
MedsAcross

Medicine

Methotrexate 50 mg/2 mL injection

Methotrexate · Intra-arterial, intramuscular, intrathecal, intravenous
Available on requestPrescription onlyUS FDAGeneric name

Methotrexate 50 mg/2 mL injection is a generic prescription medicine for intra-arterial, intramuscular, intrathecal, intravenous use, made by 3 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20° to 25°C (68° to 77°F). PROTECT FROM LIGHT.

Key facts

Active ingredient (INN)
Methotrexate
Brand
Sold under the generic name
Strength
50 mg/2 mL
Dosage form
Injection
Route
Intra-arterial, intramuscular, intrathecal, intravenous
Packs
1 vial of 2 mL, 10 vials of 2 mL
Manufacturers
Accord HealthcareIndiaHikma PharmaceuticalsTeva Parenteral Medicines
Origin register
US FDA, United States
Storage
Store at 20° to 25°C (68° to 77°F). PROTECT FROM LIGHT.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L01BA01 Methotrexate
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
31 July 2012
Identifiers
RxCUI 1655956, 1655959, 1655960 +2DailyMed set ID 346ec9ce-dc98-4a55-b55e-d3af11f2d703, dd035a9f-cd40-4314-b9d8-2294b8a924e2, 3989d30d-56e5-4e8d-9379-c30fecc894f2NDC 0703-3671, 16729-277, 0143-9519Application ANDA040843, ANDA040716, ANDA089340

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
1 vial in 1 carton / 2 mL in 1 vial16729-277-30Accord HealthcareIndia7 March 2014
10 vial in 1 carton / 2 mL in 1 vial0143-9519-10Hikma Pharmaceuticals10 October 2017
1 vial, single-dose in 1 carton / 2 mL in 1 vial, single-dose0703-3671-01Teva Parenteral Medicines8 June 2018
1 vial, single-dose in 1 carton / 2 mL in 1 vial, single-dose55150-510-01—11 September 2024
5 vial, single-dose in 1 carton / 2 mL in 1 vial, single-dose55150-510-05—11 September 2024
5 vial, multi-dose in 1 carton / 2 mL in 1 vial, multi-dose61703-161-05—4 November 2024
5 vial, multi-dose in 1 carton / 2 mL in 1 vial, multi-dose46708-711-05—15 April 2026
5 vial, multi-dose in 1 carton / 2 mL in 1 vial, multi-dose62332-711-05—15 April 2026
5 vial, multi-dose in 1 carton / 2 mL in 1 vial, multi-dose61703-350-10—25 September 2014
5 vial, multi-dose in 1 carton / 2 mL in 1 vial, multi-dose61703-350-38—27 July 2005

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 7 December 1953Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Methotrexate 50 mg/2 mL injection.

Compare all 2

Other strengths and forms of Methotrexate

Clinical summary

Methotrexate is a folate analog metabolic inhibitor indicated for neoplastic diseases for the, among other approved uses. It is available as injection, tablets and powder for injection for oral, subcutaneous and intramuscular use. MedsAcross supplies Methotrexate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Methotrexate

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Methotrexate 50 mg/2 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.